目的 观察二妙丸联合奥洛他定治疗慢性肛周湿疹的临床疗效。方法 回顾性选取2024年11月—2025年10月大同市第一人民医院收治的80例慢性肛周湿疹患者作为研究对象，根据用药方案差异将患者分为对照组和治疗组，每组各40例。对照组口服盐酸奥洛他定片，5 mg/次，早晚各1次。治疗组在对照组治疗基础上联合口服二妙丸，6 g/次，2次/d。两组连续治疗8周。观察两组临床疗效，比较两组肛周渗液情况、肛周皮损和瘙痒情况、血清细胞因子和生活质量。随访3个月，比较两组复发率。结果 治疗后，治疗组患者总有效率（97.50%）显著高于对照组（80.00%，P＜0.05）。治疗后，两组肛周渗液评分、湿疹面积与严重程度指数（EASI）评分、瘙痒视觉模拟评分法（VAS）评分与同组治疗前比较均显著降低（P＜0.05）；治疗结束治疗组肛周渗液评分、EASI评分、瘙痒VSA评分低于对照组（P＜0.05）。治疗后，两组血清免疫球蛋白E（IgE）、外周血中嗜酸性粒细胞（EOS）绝对值、皮肤病生活质量指数（DLQI）评分均显著降低（P＜0.05）；治疗后，治疗组血清IgE、EOS绝对值、DLQI评分低于对照组（P＜0.05）。随访期间，治疗组和对照组复发率分别是5.00%、20.00%，治疗组复发率显著低于对照组（P＜0.05）。结论 二妙丸联合奥洛他定治疗慢性肛周湿疹患者可显著提高临床疗效，改善肛周渗液、皮损与瘙痒，降低外周血EOS绝对值与血清IgE水平，提升患者生活质量，且患者治疗后3个月内复发风险较低，值得在临床慢性肛周湿疹患者治疗中开展。

Objective To observe the clinical efficacy of Ermiao Pills combined with olopatadine in treatment of chronic perianal eczema. Methods A retrospective selection was made of 80 patients with chronic perianal eczema who were admitted to Datong First People's Hospital from November 2024 to October 2025. The patients were divided into control group and treatment group based on the differences in medication regimens, with 40 patients in each group. Patients in control group were given oral Olopatadine Hydrochloride Tablets at a dose of 5 mg each time, taken once in morning and once in evening. Patients in treatment group were treated with the same regimen as the control group and in addition, they were given the oral formula of Ermiao Pills at a dose of 6 g each time, twice daily. Both groups were treated continuously for 8 weeks. The clinical efficacy of two groups was observed, and the conditions of perianal exudation, perianal skin lesions and itching, serum cytokines and quality of life were compared. The follow-up period was 3 months, and the recurrence rates of two groups were compared. Results After treatment, the total effective rate of treatment group (97.50%) was significantly higher than that of control group (80.00%, P < 0.05). After treatment, the levels of perianal exudation, Eczema Area and Severity Index (EASI) score, and Visual Analogue Scale (VAS) score for itching in both groups were significantly lower compared to those before treatment (P< 0.05). At the end of treatment, the levels of perianal exudation, EASI score, and VAS score for itching in treatment group were lower than those in control group (P < 0.05). After treatment, the levels of serum immunoglobulin E (IgE), absolute values of eosinophils (EOS) in peripheral blood, and Dermatology Life Quality Index (DLQI) score in both groups were significantly lower (P < 0.05). After treatment, the levels of serum IgE, absolute values of EOS, and DLQI score in treatment group were lower than those in control group (P < 0.05). During the follow-up period, the recurrence rates of treatment group and control group were 5.00% and 20.00%, respectively, and the recurrence rate of treatment group was significantly lower than that of control group (P < 0.05). Conclusion The combination of Ermiao Pills combined with olopatadine can significantly improve the clinical efficacy in patients with chronic perianal eczema, alleviate perianal exudation, skin lesions and itching, reduce the absolute value of peripheral blood EOS and serum IgE levels, enhance the life quality, and the recurrence risk is lower within 3 months after treatment. Therefore, it is worthy of being applied in the clinical treatment of chronic perianal eczema patients.

大同市重点研发计划项目（SF2025577）